OCUL Ocular Therapeutix Inc

$12.30

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 8/22/2025

About Ocular Therapeutix Inc

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. The company is headquartered in Bedford, Massachusetts.

Website: https://www.ocutx.com

Sector
LIFE SCIENCES
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1393434
Address
24 CROSBY DRIVE, BEDFORD, MA, US
Valuation
Market Cap
$1.16B
P/E Ratio
nan
PEG Ratio
0.00
Price to Book
3.69
Performance
EPS
$-1.22
Dividend Yield
—
Profit Margin
0.00%
ROE
-95.20%
Technicals
50D MA
$7.27
200D MA
$8.48
52W High
$11.78
52W Low
$4.06
Fundamentals
Shares Outstanding
159M
Target Price
$17.50
Beta
1.49

OCUL EPS Estimates vs Actual

● Estimated
● Actual

OCUL News & Sentiment

Aug 06, 2025 • Motley Fool NEUTRAL
OCUL Sales Drop 18%
Ocular Therapeutix ( NASDAQ:OCUL ) , a biotechnology company developing therapies for eye diseases, reported its second quarter results on August 5, 2025. The earnings release pointed to a significant widening in net loss due to increased research and marketing investments.
Aug 05, 2025 • Zacks Commentary NEUTRAL
Ocular Therapeutix ( OCUL ) Reports Q2 Loss, Misses Revenue Estimates
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -11.43% and -0.70%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Aug 05, 2025 • Benzinga SOMEWHAT-BULLISH
Ocular Therapeutix™ Reports Second Quarter 2025 Financial Results and Business Highlights - Ocular Therapeutix ( NASDAQ:OCUL )
Outstanding patient retention and clinical execution in complementary AXPAXLI™ SOL trials for wet AMD SOL-1 remains on track for 1Q 2026 topline data SOL-R rescue criteria streamlined and simplified with topline data expected in 1H 2027 Planning to incorporate single long-term extension study ...
Jul 22, 2025 • GlobeNewswire NEUTRAL
Ocular Therapeutix™ to Participate in Upcoming Scientific Conferences
BEDFORD, Mass., July 22, 2025 ( GLOBE NEWSWIRE ) -- Ocular Therapeutix, Inc. ( NASDAQ: OCUL, "Ocular" ) , a biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming scientific conferences in July and August 2025.
Jul 22, 2025 • Benzinga NEUTRAL
Ocular Therapeutix™ to Participate in Upcoming Scientific Conferences - Ocular Therapeutix ( NASDAQ:OCUL )
BEDFORD, Mass., July 22, 2025 ( GLOBE NEWSWIRE ) -- Ocular Therapeutix, Inc. OCUL "Ocular" ) ) , a biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming scientific conferences in July and August 2025.
Jun 26, 2025 • Benzinga NEUTRAL
Ocular Therapeutix™ Unveils New Corporate Branding, Reflecting its Transformation to a Retina-Focused Company - Ocular Therapeutix ( NASDAQ:OCUL )
BEDFORD, Mass., June 26, 2025 ( GLOBE NEWSWIRE ) -- Ocular Therapeutix, Inc. OCUL "Ocular" ) ) , a biopharmaceutical company committed to redefining the retina experience, announced the launch of its new corporate branding and website today, marking the next milestone of the Company's ...
Sentiment Snapshot

Average Sentiment Score:

0.133
50 articles with scored sentiment

Overall Sentiment:

Neutral

OCUL Reported Earnings

May 05, 2025
Mar 31, 2025 (Pre market)
0.0 Surprise
  • Reported EPS: $0.00
  • Estimate: $0.00
  • Whisper: —
  • Surprise %: 0.0%
Mar 10, 2025
Dec 31, 2024 (Pre market)
-0.07 Surprise
  • Reported EPS: $-0.29
  • Estimate: $-0.22
  • Whisper: —
  • Surprise %: -31.8%
Nov 05, 2024
Sep 30, 2024 (Post market)
0.02 Surprise
  • Reported EPS: $-0.22
  • Estimate: $-0.24
  • Whisper: —
  • Surprise %: 8.3%
Aug 07, 2024
Jun 30, 2024 (Pre market)
-0.04 Surprise
  • Reported EPS: $-0.26
  • Estimate: $-0.22
  • Whisper: —
  • Surprise %: -18.2%
May 07, 2024
Mar 31, 2024 (Post market)
-0.51 Surprise
  • Reported EPS: $-0.70
  • Estimate: $-0.19
  • Whisper: —
  • Surprise %: -268.4%
Mar 11, 2024
Dec 31, 2023 (Post market)
-0.05 Surprise
  • Reported EPS: $-0.35
  • Estimate: $-0.30
  • Whisper: —
  • Surprise %: -16.7%
Nov 07, 2023
Sep 30, 2023 (Post market)
0.12 Surprise
  • Reported EPS: $-0.17
  • Estimate: $-0.29
  • Whisper: —
  • Surprise %: 41.4%
Aug 07, 2023
Jun 30, 2023 (Post market)
0.04 Surprise
  • Reported EPS: $-0.26
  • Estimate: $-0.30
  • Whisper: —
  • Surprise %: 13.3%
May 08, 2023
Mar 31, 2023 (Post market)
-0.13 Surprise
  • Reported EPS: $-0.39
  • Estimate: $-0.26
  • Whisper: —
  • Surprise %: -50.0%

Financials